Decode Health
Decode Health is a Nashville-based precision medicine R&D company that operates a cloud-native AI platform integrating multiomics, clinical, and real-world data to accelerate biomarker discovery and clinical decision support for pharmaceutical, diagnostics, and health technology clients.
- Company typePrivate
- Founded2019
- HeadquartersNashville, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Decode Health does
Decode Health is a Nashville-based precision medicine R&D company that operates a cloud-native AI platform for biomarker discovery and clinical decision support. Founded in 2019, the company integrates multiomic, clinical, claims, and real-world data through automated analytics, competitive ML modeling across multiple algorithm families, and generative AI-driven hypothesis generation. Its disease-agnostic platform has been validated across autoimmune disease, oncology, sepsis, neurology, and gastroenterology, and is supported by proprietary IRB-approved patient cohorts combined with public multiomics datasets and licensed claims/EHR data. Validated technical performance includes 94% accuracy distinguishing NMO from RRMS (Journal of Molecular Diagnostics, 2024), 90% prediction of four-month healthcare spend for top-cost MS patients vs. 42% with conventional methods (Communications Medicine, 2025), and AUC values up to 0.947 for sepsis severity classification (AMP 2025).
The company serves pharmaceutical, molecular diagnostics, and health technology clients with structured, phase-gated R&D programs that begin with a Discovery Sprint and progress through Platform Development into Results. Named enterprise relationships include Quest Diagnostics, Briya, Spesana (now Arancia), an unnamed leading medical device company (sepsis RNA biomarkers delivered in under one month), and an unnamed global pharmaceutical company (oncology risk stratification on a 2.1M-life claims dataset). Revenue streams include bespoke R&D program services, biomarker discovery research engagements, validated risk model licensing, and non-dilutive NIH/NIAID SBIR funding (cumulative $2.2M+, with a $1.9M Phase II SBIR awarded in August 2025 for blood-based MS diagnostics).
Decode Health distributes exclusively through direct enterprise sales in the U.S. domestic market, supplemented by scientific conference presence (ACTRIMS, ECTRIMS, AMP, CMSC), peer-reviewed publications, podcasts, and PR in healthcare trade outlets. Commercial arrangements expand from initial defined-scope engagements into licensing, milestone-based, or revenue-sharing structures as programs demonstrate value. The company maintains academic ties to Vanderbilt University Medical Center and the University of Miami Miller School of Medicine, and collaborates with Broad Clinical Labs and the Accelerated Cure Project for MS on the NIH-funded MS biomarker program.
Decode Health firmographics
Firmographics- Name
- Decode Health
- Legal name
- Decode Health, Inc.
- Website
- https://decodehealth.ai
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Decode Health is a Nashville-based precision medicine R&D company that operates a cloud-native AI platform integrating multiomics, clinical, and real-world data to accelerate biomarker discovery and clinical decision support for pharmaceutical, diagnostics, and health technology clients.
- Ownership category
- akta.pro rank
Decode Health industry classification
Industry- Product category
- Precision Medicine R&D / Multiomics Analytics
- NAICS
- Scientific Research and Development Services (5417), Medical and Diagnostic Laboratories (6215)
- SIC
- Services-Computer Processing & Data Preparation (7374), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)
- akta.pro secondary industries
- Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO), Data Management, Biostatistics & Statistical Programming FSP (HLAGAOAB)
Keywords
Where Decode Health is headquartered
LocationHeadquarters
- HQ city
- Nashville
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Decode Health business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- R&D Program Services (Pharma, Diagnostics, Health Tech): Structured R&D programs with defined phases, fixed deliverables, and decision gates. Programs start with a defined scope so partners can evaluate on real results before expanding. Commercial structures broaden into licensing, milestone-based arrangements, or revenue-sharing models as programs demonstrate value.
- Biomarker Discovery Research Engagements: Partner-funded research programs producing ranked biomarker panels with standardized result packages structured for scientific and commercial review, regulatory, diligence, or commercialization use.
- NIH/NIAID SBIR Funding: Non-dilutive federal funding through Small Business Innovation Research grants. Currently $1.9M Phase II SBIR (R44AI195280) for blood-based MS diagnostics (2025-2027), plus prior $248K grant for progressive MS detection.
- Validated Risk Model Licensing: Validated risk models with clinical and economic context available for payer, partner, or licensing conversations. IP produced with commercial value in every program, terms structured to align incentives around outcomes.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels8 records
Decode Health product offering
Product offeringCore offering
Decode Health runs precision medicine R&D programs for pharmaceutical, diagnostics, and health technology partners using a cloud-native AI platform that combines automated multiomics, clinical, and real-world data analytics with proprietary patient cohorts. Engagements move from a Discovery Sprint through structured Platform Development to validated findings (ranked biomarker panels or ML risk models) in weeks rather than months, with commercial structures spanning licensing, milestone-based, or revenue-sharing arrangements. The platform has been validated across autoimmune, neurology, oncology, sepsis, and gastroenterology.
Product overview
Decode Health offers a cloud-native precision medicine R&D platform as its core product, combining automated multiomics and clinical analytics with proprietary patient data and deep scientific expertise. The platform operates through three structured phases and delivers results in weeks rather than months. Two primary application modules sit atop the platform: Biomarker & Molecular Discovery (multiomics/RNA-seq analytics for disease signatures and therapeutic targets) and Clinical Risk Prediction & Decision Support (claims/EHR-based ML models for patient risk stratification). The NIH-Funded MS Biomarker Program represents a specific, NIH-funded instantiation of the biomarker discovery module targeting multiple sclerosis. The platform is disease-agnostic, validated across autoimmune disease, oncology, sepsis, neurology, and gastroenterology.
Differentiator
Problem solved
Functional benefit
Products and services
- Decode Health Precision Medicine R&D Platform Cloud-native AI analytics platform combining automated multiomics, clinical, and real-world data integration with deep scientific expertise to accelerate biomarker discovery and clinical decision support. Programs run through three structured phases (Discovery Sprint, Platform Development, Results For Your Next Stage) and deliver validated, commercially actionable results in weeks rather than months. Targeted at pharmaceutical, diagnostics, and health technology teams.
- Biomarker & Molecular Discovery Multiomics analytics service combining deep RNA-seq expertise with clinical data to identify disease signatures, candidate biomarkers, and therapeutic targets across autoimmune, neurodegenerative disease, oncology, and infectious disease areas. Delivers ranked candidate biomarker panels in under one month with a defined path to analytical validation.
- Clinical Risk Prediction & Decision Support ML models built on real-world claims and EHR data that prospectively identify rising-risk patients before they become high-cost, supporting clinical decision support and population health applications. Validated publications include Communications Medicine (Nature Portfolio) and BMJ Health & Care Informatics covering MS and Crohn's disease high-spend prediction.
- NIH-Funded MS Biomarker Program $1.9M NIH/NIAID Phase II SBIR funded program producing a blood-based, AI-driven readout of MS disease biology from a single tube of blood, in collaboration with Broad Clinical Labs and Accelerated Cure Project for MS. Generates objective, scalable disease state and progression readouts for MS.
Quantifiable outcome
- 5-18x faster R&D timelines: programs move from question to validated findings in weeks, not months
- +8 more outcomes
Companies that use Decode Health
Customer profileNamed customers5 records
Segments4 records
Ideal customer profiles4 records
Decode Health technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability8 records
Feature6 records
Decode Health partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core and minor.
- Circular GenomicscoreResearch collaboration focused on circular RNA biomarkers for multiple sclerosis detection and monitoring. Decode Health contributes its NIH-funded MS biomarker program and AI analytics platform; Circular Genomics brings its circRNA platform and assay development capabilities. The goal is to develop circRNA signatures enabling earlier MS detection and disease progression tracking. Circular Genomics recently closed a $15M Series A and holds exclusive IP licenses from Washington University and Max Delbrück Center for use in Alzheimer's disease.
- Broad Clinical LabscoreCollaboration partner on the $1.9M NIH/NIAID Phase II SBIR grant for blood-based MS diagnostics. Broad Clinical Labs provides high-throughput sequencing and multiomics laboratory expertise. Chief Commercial Officer Tim De Smet stated the partnership aims to turn cutting-edge science into practical solutions for how MS is studied and treated.
- Accelerated Cure Project for MScoreCollaboration partner on the $1.9M NIH/NIAID Phase II SBIR grant. ACP engages the patient community, provides biosamples, and champions open data sharing. Chief Scientific Officer Stephanie Buxhoeveden noted that working with Decode Health allows ACP's biosamples and perspectives to shape an innovative approach that could improve MS care and speed new therapies.
- Vanderbilt University Medical CenterminorAcademic collaboration partner on the $1.9M NIH/NIAID Phase II SBIR grant and other research programs. Dr. Ram Sriram, Director of Vanderbilt's MS Clinic, noted that a reliable blood-based MS approach could transform how providers counsel patients and choose therapies. Additional Decode team members have appointments at Vanderbilt.
- University of Miami Miller School of MedicineminorAcademic collaboration partner contributing clinical and bioinformatics insights and participant recruitment for the $1.9M NIH/NIAID Phase II SBIR grant. Dr. Yan Guo, Professor of Public Health Sciences and Director of Biostatistics and Bioinformatics Shared Resource at Sylvester Comprehensive Cancer Center, noted the collaboration could set a new standard for integrating multiomics data into practical healthcare tools.
- Quest DiagnosticscoreJoint research collaboration with joint presentation at the American Academy of Neurology 2023 Annual Meeting. Quest Diagnostics and Decode Health jointly presented research demonstrating RNA-seq-based ML classification of NMO vs. MS, with identification of actionable therapeutic targets. Quest provides nationally scaled sequencing, research, and patient engagement platform to empower life science organizations.
- BriyacoreData-sharing partnership to advance precision medicine through decentralized data exchange. Briya provides an end-to-end decentralized data exchange platform. The partnership enables Decode and Briya customers to access new data and analytics for development of clinical decision support tools, diagnostic testing, and new treatments. CEO David Lazerson noted the combined data framework would empower researchers and life sciences developers to access high-resolution data for better testing and new treatments.
- Spesana (now Arancia)minorStrategic alignment on precision medicine and value-based care models. Spesana Founder Carla Balch noted alignment with Decode's mission and excitement to launch additional capabilities for clinicians, biopharma, molecular diagnostics, and payers. Spesana focuses on enabling dynamic molecular diagnostics and real-world data utilization in clinical workflows.
- Agilent TechnologiesminorCo-development of a technical whitepaper on Pre-Analytical RNA Integrity Assessment for Sequencing-Based Biomarker Discovery, companion to Decode's JMD QC Framework publication. Co-presented a webinar on end-to-end QC processes for RNA biomarker discovery. Agilent provides technical expertise and co-branded educational content for the precision medicine community.
Scale indicators8 records
Recent moves6 records
Expansion highlights5 records
Decode Health competitors and assessment
Company assessmentBroad incumbents
- Veracyte: Molecular diagnostics company developing genomic tests across oncology and other indications. Comparable to Decode in translating multiomics/R&D findings into clinically actionable diagnostics, though Veracyte is more established and commercially focused on uveal melanoma and thyroid.
- Flatiron Health: Real-world oncology data and analytics platform serving pharma R&D and clinical decision support. Comparable to Decode's real-world data and claims-based ML risk prediction services, though Flatiron is much larger and oncology-only.
- Tempus Labs: AI-driven precision medicine company offering multiomics biomarker discovery, molecular profiling, and data analytics for pharma and providers. Comparable to Decode in targeting pharma R&D with AI/multiomics, but operates at substantially larger scale with broader product portfolio.
- Foundation Medicine: Established molecular diagnostics company (Roche subsidiary) providing comprehensive genomic profiling assays and pharma biomarker services. Comparable to Decode in molecular diagnostics for pharma, but operates at much larger commercial scale and is more oncology-focused.
Direct peers
- Owkin: AI biomarker discovery platform using federated learning and multiomics to accelerate drug development for pharma. Directly comparable to Decode's AI-driven biomarker discovery for pharma, though Owkin is more focused on oncology and has broader European footprint.
- SOPHiA Genetics: AI-driven platform for genomics and multiomics data analysis used by hospitals, labs, and biopharma. Closely comparable to Decode in the AI multiomics analysis space for both clinical and research applications, with a broader installed base across global healthcare systems.
- Insitro: AI/ML-driven drug discovery and biomarker platform combining multiomics data with machine learning for pharma. Comparable to Decode's AI/ML + multiomics approach to pharma R&D, though insitro focuses more on therapeutic discovery rather than biomarker/decision support.
- Personalis: Cancer genomics and multiomics company serving pharma with biomarker discovery and clinical trial assays. Comparable to Decode in providing multiomics-based biomarker discovery services to pharma, though Personalis is more oncology-focused.
- BC Platforms: Genomics and real-world data analytics platform serving pharma R&D with biomarker discovery and translational research. Comparable to Decode's combination of multiomics analytics, claims/EHR data, and pharma R&D services, with stronger European presence.
Emerging players
- PathAI: AI-driven pathology and biomarker discovery company serving pharma with computational diagnostics and tissue-based analytics. Adjacent comparable to Decode in AI diagnostics for pharma, but PathAI specializes in pathology/imaging rather than RNA-seq/multiomics.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Decode Health social profiles
Digital presenceDecode Health compliance and trust
Trust signalCompliance3 records
Decode Health financial estimates
Financial estimateRevenue estimate
Valuation estimate
Decode Health leadership team
Management profileNumber of profiles
Profiles9 records
Decode Health funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Decode Health M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Decode Health
What does Decode Health do?
Decode Health runs precision medicine R&D programs for pharmaceutical, diagnostics, and health technology partners using a cloud-native AI platform that combines automated multiomics, clinical, and real-world data analytics with proprietary patient cohorts. Engagements move from a Discovery Sprint through structured Platform Development to validated findings (ranked biomarker panels or ML risk models) in weeks rather than months, with commercial structures spanning licensing, milestone-based, or revenue-sharing arrangements. The platform has been validated across autoimmune, neurology, oncology, sepsis, and gastroenterology.
Is Decode Health a public or private company?
Decode Health is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Decode Health founded?
Decode Health was founded in 2019. It employs 11 to 50 people.
Where is Decode Health based?
Decode Health is headquartered in Nashville, United States, in the North America region.
How does Decode Health make money?
Four revenue lines are on record. R&D Program Services (Pharma, Diagnostics, Health Tech) is the primary driver. The others are biomarker Discovery Research Engagements, NIH/NIAID SBIR Funding and validated Risk Model Licensing.
Who are Decode Health's main competitors?
Broad incumbents on record are Veracyte, Flatiron Health, Tempus Labs and Foundation Medicine. Direct peers are Owkin, SOPHiA Genetics, Insitro, Personalis and BC Platforms. PathAI is listed as an emerging player.
Does Decode Health have an API?
No public API is recorded for Decode Health.
What industry is Decode Health in?
Decode Health's product category is Precision Medicine R&D / Multiomics Analytics. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAAALAO, Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays). Its NAICS code is 5417 and its SIC code is 7374.